Trials: Influenza A H3N2

Phase 2 N=145 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Influenza

Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711

Barinthus Biotherapeutics Results Mar 2021 0.8% serious AE View details

N/A N=46 Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Influenza

Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL

Hvivo Results Jan 2020 0.0% serious AE View details

Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

Influenza

Primary: Number and Percentage of Participants With Symptomatic Influenza Virus Infection After Challenge. — 4; 5; 28; 0 Participants

National Institute of Allergy and Infectious… Results Nov 2023 0.0% serious AE View details

N/A N=33 Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

Influenza A H3N2

Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events

Hvivo Results Apr 2026 0.0% serious AE View details

Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Avian Influenza · H1N1 Influenza · Influenza

Primary: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H7N9 Vaccine, With and Without Adjuvant) — 80.0; 0 percentage of participants

National Institute of Allergy and Infectious… Results Jan 2022 3.3% serious AE View details

Phase 1 N=38 Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Influenza

Primary: Percentage of Participants With Immediate Reactions — 0; 0; 28; 10 Participants

PATH Results Feb 2019 0.0% serious AE View details

Phase 1 N=43 H3N2 M2SR in Pediatric Population

Influenza · Influenza Immunisation

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) — 0; 0 Participants

National Institute of Allergy and Infectious… Results Oct 2021 0.0% serious AE View details

Phase 2 N=304 2017 A/H7N9 IIV Revaccination

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutination Inhibition (HAI) Antibodies on Day 22 Against the 2017 Influenza A/H7N9 Vaccine Virus — 22.7; 116.1; 77.7; 190.3…

National Institute of Allergy and Infectious… Results Jul 2021 0.7% serious AE View details

Phase 1 N=206 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Influenza A

Primary: Number of Participants With Local and Systemic Adverse Events (AEs) Through 29 Days Post-vaccination With Bris10 M2SR and Cumulatively Through Day 209 — 28; 24…

FluGen Inc Results Mar 2022 0.5% serious AE View details

Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies — 23.3; 19.9; 24.2; 6.0 titer

National Institute of Allergy and Infectious… Results May 2021 3.2% serious AE View details

Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Influenza

Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…

Abbott Results Dec 2016 0.0% serious AE View details

Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults

Influenza

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants

National Institute of Allergy and Infectious… Results Oct 2020 1.5% serious AE View details

Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutinin Inhibition (HAI) Antibodies Against the Influenza A/H7N9 Study Vaccine Viruses on Day 43 in Participants Who Received…

National Institute of Allergy and Infectious… Results Aug 2021 2.2% serious AE View details

Phase 2 N=720 Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies — 33.6; 33.5; 39.2; 5.5 titer

National Institute of Allergy and Infectious… Results Oct 2020 2.9% serious AE View details

Phase 2 N=405 Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

Pandemic · Avian Influenza

Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects

Novartis Results Feb 2013 3.5% serious AE View details

Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Influenza

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants

National Institute of Allergy and Infectious… Results Feb 2023 0.0% serious AE View details

Phase 1 N=122 Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Influenza Vaccine

Primary: Treatment Emergent AEs During 7 Days After Experimental Treatment — 1; 0; 12; 3 Participants

FluGen Inc Results Jun 2023 0.0% serious AE View details

Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Avian Influenza · Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Against the 2017 H7N9 Inactivated Influenza Vaccine (IIV) Strain After Second H7N9…

National Institute of Allergy and Infectious… Results Aug 2020 0.7% serious AE View details

Phase 2 N=179 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Influenza

Primary: Number of Subjects With Influenza-like Clinical Illness and Laboratory Confirmed Infection Post Challenge With a Homologous A Strain Influenza Virus — 17; 19; 15…

Vaxart Results Oct 2022 0.0% serious AE View details

N/A N=4,561 Influenza Resistance Information Study

Influenza

Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants

Hoffmann-La Roche Results Jul 2016 0.8% serious AE View details

Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3

Influenza, Human

Primary: Number and Percentage of Subjects Experiencing Solicited Local Adverse Events (AE) — 1; 0; 1; 0 Participants

Institute of Vaccines and Medical Biologicals… Results Jul 2019 0.7% serious AE View details

Phase 2 N=275 Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Influenza

Primary: Number of Subjects With a Hemagglutination Inhibition (HI) Antibody Response to the Vaccine Strain (A/H9N2/Chicken/Hong Kong/G9/97) Associated With Seroconversion 21…

Alachua Government Services, Inc. Results Feb 2023 0.0% serious AE View details

Phase 4 N=12 Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Influenza A Subtype H5N1 Infection

Primary: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29 After Vaccination With the Seasonal…

Emory University Results Mar 2020 0.0% serious AE View details

Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza · Healthy

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0.4; 0.0 percentage of participants

MedImmune LLC Results Nov 2014 1.0% serious AE View details

Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza · Influenza Vaccines

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

GlaxoSmithKline Results Feb 2020 0.8% serious AE View details

Phase 2 N=833 A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

Primary: Percentage of Seroprotected Participants for Anti-hemagglutination Inhibition (HI) Antibodies Against Vaccine-homologous H7N9 — 27.1; 27.7; 23.5; 26.5 Percentage of…

GlaxoSmithKline Results Oct 2023 4.6% serious AE View details

Phase 1 N=40 Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Influenza

Primary: Adverse Events by Severity — 20; 8; 25; 8 Participants

PATH Results Nov 2018 0.0% serious AE View details

Phase 2 N=260 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Influenza, Human · Influenza in Birds · Respiratory Tract Infections

Primary: Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HI) Antibodies Against the H5N6 Strain — 5.48; 5.55; 5.47; 20.39 titer

Seqirus Results May 2026 3.9% serious AE View details

Phase 4 N=303 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Influenza

Primary: Percentage of Participants Reporting Fever Within 7 Days Post Vaccination — 0.0; 1.7 Percentage of Participants

MedImmune LLC Results Feb 2014 0.7% serious AE View details

Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

Influenza Infection

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants

National Institute of Allergy and Infectious… Results Apr 2022 0.0% serious AE View details

Clinical Trial Search

Phase 2 N=145 Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

N/A N=46 Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Phase 1 N=60 Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

N/A N=33 Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain

Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Phase 1 N=38 Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine

Phase 1 N=43 H3N2 M2SR in Pediatric Population

Phase 2 N=304 2017 A/H7N9 IIV Revaccination

Phase 1 N=206 Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Phase 3 N=120 Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season

Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults

Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval

Phase 2 N=720 Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Phase 2 N=405 Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

Phase 1 N=25 Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Phase 1 N=122 Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Phase 2 N=179 A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

N/A N=4,561 Influenza Resistance Information Study

Phase 3 N=889 Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3

Phase 2 N=275 Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Phase 4 N=12 Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Phase 4 N=300 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Phase 2 N=833 A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Phase 1 N=40 Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Phase 2 N=260 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Phase 4 N=303 A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults